Abstract
Antecedent hypertension adversely affects mortality and heart failure after myocardial infarction (MI). In addition, accelerated ventricular remodeling is a contributor to the increased mortality observed after MI. The purpose of this study was to assess the relationship of antecedent hypertension to ventricular remodeling after MI. Ninety-four patients presenting with a first acute MI who were treated with reperfusion therapy within 12 h of their symptom onset were enrolled in this study. All of them underwent left ventriculography immediately after reperfusion therapy and again at 6 months after the occurrence of MI. Patients were divided into two groups: a hypertensive group and a normotensive group. End-diastolic volume index (EDVI), end-systolic volume index (ESVI), and ejection fraction (EF) values in the acute phase were compared to those at 6 months after acute MI in either group. The hypertensive group showed a significant increase in both EDVI and ESVI after 6 months, whereas the normotensive group did not. In addition, there was no change in EF in the hypertensive group, whereas EF increased significantly after 6 months in the normotensive group. As a result, the percent changes in ESVI and EF were significantly different between the hypertensive group and normotensive group. The results demonstrated that antecedent hypertension interacts with ventricular cavity dilatation after MI.
Similar content being viewed by others
Article PDF
References
Gustafsson F, Kober L, Torp-Pedersen C, et al: Long-term prognosis after acute myocardial infarction in patients with a history of arterial hypertension. Eur Heart J 1998; 19: 588–594.
Njolstad I, Arnesen E : Preinfarction blood pressure and smoking are determinants for a fatal outcome of myocardial infarction: a prospective analysis from the Finnmark Study. Arch Intern Med 1998; 158: 1326–1332.
Herlitz J, Bang A, Karlson BW : Five-year prognosis after acute myocardial infarction in relation to a history of hypertension. Am J Hypertens 1996; 9: 70–76.
Rutherford JD, Pfeffer MA, Moye LA, et al: Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. Circulation 1994; 90: 1731–1738.
Berton G, Cordiano R, Mbaso S, De Toni R, Mormino P, Palatini P : Prognostic significance of hypertension and albuminuria for early mortality after acute myocardial infarction. J Hypertens 1998; 16: 525–530.
Kober L, Torp-Pedersen C, Pedersen OD, Hoiberg S, Camm AJ : Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 1996; 78: 1124–1128.
Spencer FA, Meyer TE, Goldberg RJ, et al: Twenty year trends (1975–1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999; 34: 1378–1387.
Vogt M, Strauer BE : Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Am J Cardiol 1995; 76: 48D–53D.
Schwartzkopff B, Strauer BE : Squeezing tubes: a case of remodeling and regulation: coronary reserve in hypertensive heart disease. Cardiovasc Res 1998; 40: 4–8.
Rossi MA : Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031–1041.
Rizzello V, Poldermans D, Boersma E, et al: Opposite patterns of left ventricular remodeling after coronary revascularization in patients with ischemic cardiomyopathy: role of myocardial viability. Circulation 2004; 110: 2383–2388.
MacMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774.
Neaton JD, Wentworth D : Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med 1992; 152: 56–64.
Strauer BE : Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol 1979; 44: 999–1006.
Strauer BE : Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure. Am J Cardiol 1990; 65: 34G–41G.
Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK : The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–1562.
Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D : Profile for estimating risk of heart failure. Arch Intern Med 1999; 159: 1197–1204.
Ho KK, Pinsky JL, Kannel WB, Levy D : The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22: 6A–13A.
Pfeffer MA, Braunwald E : Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161–1172.
Warren SE, Royal HD, Markis JE, Grossman W, McKay RG : Time course of left ventricular dilation after myocardial infarction: influence of infarct-related artery and success of coronary thrombolysis. J Am Coll Cardiol 1988; 11: 12–19.
Takano H, Zou Y, Akazawa H, et al: Inhibitory molecules in signal transduction pathways of cardiac hypertrophy. Hypertens Res 2002; 25: 491–498.
Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
Yui Y, Sumiyoshi T, Kodama K, et al: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–191.
Fukui T, Rahman M, Hayashi K, et al: Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 2003; 26: 979–990.
Staessen JA, Wang JG, Thijs L : Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–1076.
Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669–677.
Pfeffer MA : Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 1995; 46: 455–466.
Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico : GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–1122.
Ambrosioni E, Borghi C, Magnani B : The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80–85.
Kober L, Torp-Pedersen C, Carlsen JE, et al: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670–1676.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group : ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685.
Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H : Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–684.
HOPE Study Investigators : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145.
Fox KM : Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.
Braunwald E, Domanski MJ, Fowler SE, et al: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoshiyama, M., Kamimori, K., Shimada, Y. et al. Left Ventricular Remodeling after Myocardial Infarction in Antecedent Hypertensive Patients. Hypertens Res 28, 293–299 (2005). https://doi.org/10.1291/hypres.28.293
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.293